| Literature DB >> 21519856 |
Edyta Gendaszewska-Darmach1, Marta Kucharska.
Abstract
With a growing interest of the involvement of extracellular nucleotides in both normal physiology and pathology, it has become evident that P2 receptor agonists and antagonists may have therapeutic potential. The P2Y2 receptor agonists (diquafosol tetrasodium and denufosol tetrasodium) are in the phase 3 of clinical trials for dry eye and cystic fibrosis, respectively. The thienopyridine derivatives clopidogrel and ticlopidine (antagonists of the platelet P2Y12 receptor) have been used in cardiovascular medicine for nearly a decade. Purines and pyrimidines may be of therapeutic potential also in wound healing since ATP and UTP have been shown to have many hallmarks of wound healing factors. Recent studies have demonstrated that extracellular nucleotides take part in all phases of wound repair: hemostasis, inflammation, tissue formation, and tissue remodeling. This review is focused on the potent purines and pyrimidines which regulate many physiological processes important for wound healing.Entities:
Year: 2011 PMID: 21519856 PMCID: PMC3146642 DOI: 10.1007/s11302-011-9233-z
Source DB: PubMed Journal: Purinergic Signal ISSN: 1573-9538 Impact factor: 3.765
Fig. 1Cellular events during different stages of wound healing
Expression of P2 receptor subtypes on cells involved in wound healing
| Cell type | Receptor subtypes | Method of detection | References |
|---|---|---|---|
| Keratinocytes | |||
| NHK | P2Y1, P2Y2, P2Y4, P2Y6 P2X1, P2X4, P2X5, P2X6, P2X7, P2Y1, P2Y2, P2Y4, P2Y11, P2Y12, and P2Y13 | RT-PCR | [ |
| RT-PCR | [ | ||
| HaCaT | P2X5, P2X6, P2Y1, P2Y2, P2Y6, P2Y11, P2Y12 >> P2X7, P2Y4 | RT-PCR | [ |
| Dermal fibroblasts | P2X4, P2X7 > P2X3 | RT-PCR | [ |
| P2Y1, P2Y2, P2Y4, P2Y6 | |||
| Skin MC | P2X1 >> P2X4 | GeneChip | [ |
| Endothelium | |||
| HUVEC | P2X4 > P2Y11 > P2Y1 > P2Y2 >> P2Y4, P2Y6 | RT-qPCR and Wb | [ |
| P2X4 >> P2X7 > P2Y1 > P2Y2 | Competitive PCR analysis | [ | |
| P2X4 = P2X6 | Confocal and electron microscopy | [ | |
| HAECs | P2X4 >> P2X7 > P2Y1 > P2Y2 | Competitive PCR analysis | [ |
| HPAEC | P2X4 | Nb | [ |
| HMVEC | P2X4 | Nb | [ |
| HMEC-1 | P2X4, P2X5, P2X7, P2Y2, P2Y11 > P2X1 | RT-PCR | [ |
| VSMCs | P2X1 > P2Y2, P2X4 > P2Y6 > P2Y1, P2Y4 | RT-qPCR and Wb | [ |
| Endothelium-denuded cerebral arteries | P2X1 > P2Y2 > P2Y6 > P2Y1 >> P2Y4 | RT-PCR | [ |
| Endothelium-denuded omental arteries | P2X1 > P2Y1, P2Y2, P2Y6 | RT-PCR | [ |
Wb Western blot, Nb Northern blot, MC mast cells, qPCR quantitative PCR, RT-PCR reverse transcription PCR, HPAECs human pulmonary artery ECs, HMVEC human microvessel endothelial cell, HMEC-1 transformed human microvascular endothelial cell line one
Immune cell distribution of nucleotide receptor subtypes
| Subtype | Immune cell distribution | References |
|---|---|---|
| P2X1 | Neutrophils, eosinophils, lymphocytes, lymphocytes, monocytes, dendritic cells | [ |
| P2X2 | Lymphocytes | [ |
| P2X3 | ||
| P2X4 | Eosinophils, lymphocytes, monocytes, dendritic cells | [ |
| P2X5 | Dendritic cells | [ |
| P2X6 | ||
| P2X7 | Eosinophils, B lymphocytes, T lymphocytes, monocytes, macrophages, dendritic cells | [ |
| P2Y1 | Neutrophils, eosinophils, lymphocytes, monocytes, dendritic cells | [ |
| P2Y2 | Neutrophils, eosinophils, polymorphonuclear neutrophils, lymphocytes, monocytes, macrophages, dendritic cells | [ |
| P2Y4 | Neutrophils, eosinophils, lymphocytes, monocytes, macrophages, dendritic cells | [ |
| P2Y6 | Neutrophils, eosinophils, lymphocytes, monocytes, macrophages, dendritic cells | [ |
| P2Y11 | Neutrophils, eosinophils, lymphocytes, monocytes, dendritic cells | [ |
| P2Y12 | Monocytes, lymphocytes, dendritic cells | [ |
| P2Y13 | Monocytes, lymphocytes, | [ |
| P2Y14 | Eosinophils, dendritic cells | [ |